Staff Profile

Roles and Responsibilities

I am Clinical Senior Lecturer at Newcastle University and Consultant Psychiatrist in inpatient services  care with the NTW Foundation NHS Trust. I work also with the Clinical Research Network. In the North-East and North Cumbria, I am co-lead for mental health, and deputy industry lead (cross-specialty) with a lead role in investigator initiated trials and, nationally, I am workstream lead for commercial research.

Qualifications

MBBS 1992
MRCPsych 1998
MD (HPA axis in mood disorder patients 2004)

Memberships

British Medical Association

British Association for Psychopharmacology

Royal College of Psychiatrists

Research Interests

I am interested in the pathophysiogy of mood disorders, particularly bipolar disorder, the role of childhood experience and the application of this understanding to develop new treatment strategies.

Current Work

I have recently completed a treatment trial using a cortisol synthesis inhibitor in treatment resistant depression and an examination of the pathophysiology of chronic fatigue syndrome. I am involved in study which is examining language use in schizophrenia in order to better understand its psychopathology. 

I am examining the impact of early childhood adversity on adult mood, brain (hippocampal) function and on the stress hormone system 

Future Research

I think that there is tremendous potential to examine drugs that act on the HPA axis as new treatment strategies and I am interested in further exploring the links between early adversity, immune system, the HPA axis and illness.

Esteem Indicators

NARSAD Young Investigator Award (Cytokines in bipolar patients)
HEFCE Clinical Senior Lecturer Award

Funding

Stanley Medical Research Institute
MRC

• Articles

  • Martins-Correia J, Fernandes LA, Kenny R, Salas B, Karmani S, Inskip A, Pearson F, Watson S. Cariprazine in the acute treatment of unipolar and bipolar depression: A systematic review and meta-analysis. Journal of Affective Disorders 2024, 362, 297-307.
  • Hoppe I, Watson S, Kemp C, Turnbull F, Davies F, Gibson J, Azim L, Wall L, Ahuja N, Al-Ashmori S, Keys S, Kabir T, Chew-Graham CA. Aripiprazole/Sertraline Combination: Clinical and Cost-Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)—Protocol for a Nested Qualitative Study. Health Expectations 2024, 27(5), e70018.
  • Tarn J, Evans E, Traianos E, Collins A, Stylianou M, Parikh J, Bai Y, Guan Y, Frith J, Lendrem D, Macrae V, McKinnon I, Simon BS, Blake J, Baker M, Taylor J-P, Watson S, Gallagher P, Blamire A, Newton J, Ng W-F. The Effects Of Non-Invasive Vagus Nerve Stimulation on Fatigue In Participants With Primary Sjögren's Syndrome. Neuromodulation: Technology at the Neural Interface 2023, 26(3), 681-689.
  • Clark JE, Watson S. Modelling mood updating: a proof of principle study. The British journal of psychiatry : the journal of mental science 2023, 222(3), 125-134.
  • Costa T, Rushton SP, Watson S, Ng W-F. Depression in Sjögren's syndrome mediates the relationship between pain, fatigue, sleepiness, and overall quality of life. Rheumatology and Immunology Research 2023, 4(2), 78-89.
  • Costa T, Taylor A, Black F, Hill S, McAllister-Williams RH, Gallagher P, Watson S. Autonomic dysregulation, cognition and fatigue in people with depression and in active and healthy controls: observational cohort study. BJ Psych Open 2023, 9(4), e106.
  • Au-Yeung SK, Griffiths J, Roberts S, Edwards C, Yu L-M, Bogacz R, Rendell J, Attenburrow M-J, Watson S, Chan F, Cipriani A, Cleare A, Harmer CJ, Kessler D, Evans J, Lewis G, Singh I, Simon J, Harrison PJ, Cowen P, Shanyinde M, Geddes J, Browning M. PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression. Evidence-Based Mental Health 2022, 25(2), 77-83.
  • Azim L, Hindmarch P, Browne G, Chadwick T, Clare E, Courtney P, Dixon L, Duffelen N, Fouweather T, Geddes JR, Goudie N, Harvey S, Helter T, Holstein EM, Martin G, Mawson P, McCaffery J, Morriss R, Simon J, Smith D, Stokes P, Walker J, Weetman C, Wolstenhulme F, Young AH, Watson S, McAllister-Williams H. Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study). BMC Psychiatry 2021, 21(21), 334.
  • Elliott AL, Watson S, Dodgson G, Cohen-Tovee E, Ling J. Changing practice: Assessing attitudes toward a NICE-informed collaborative treatment pathway for bipolar disorder. BJPsych Open 2021, 7(2), e64-e64.
  • Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Florio AD, Dietch D, Geddes JR, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, McAllister-Williams RH, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. British Journal of Psychiatry 2019, 214(1), 27-35.
  • Deamer F, Palmer E, Vuong QC, Ferrier N, Finkelmeyer A, Hinzen W, Watson S. Non-literal understanding and psychosis: Metaphor comprehension in individuals with a diagnosis of schizophrenia. Schizophrenia Research: Cognition 2019, 18, 100159.
  • Clark JE, Ng W-F, Rushton S, Watson S, Newton JL. Network structure underpinning (dys) homeostasis in chronic fatigue syndrome; Preliminary findings. PLoS ONE 2019, 14(3), e0213724.
  • Franklin M, Mukuria C, Mulhern B, Tran I, Brazier J, Watson S. Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity. The Patient - Patient-Centred Outcomes Research 2019, 12, 405-417.
  • Little B, Gallagher P, Zimmerer V, Varley R, Douglas M, Spencer H, Çokal D, Deamer F, Turkington D, Ferrier IN, Hinzen W, Watson S. Language in schizophrenia and aphasia: the relationship with non-verbal cognition and thought disorder. Cognitive Neuropsychiatry 2019, 24(6), 389-405.
  • Robinson LJ, Gallagher P, Watson S, Pearce R, Finkelmeyer A, MacLachlan L, Newton JL. Impairments in cognitive performance in chronic fatigue syndrome are common, not related to co-morbid depression but do associate with autonomic dysfunction. PLoS ONE 2019, 14(2), e0210394.
  • Cokal D, Zimmerer V, Turkington D, Ferrier N, Varley R, Watson S, Hinzen W. Disturbing the rhythm of thought: Speech pausing patterns in schizophrenia, with and without formal thought disorder. PLoS ONE 2019, 14(5), e0217404.
  • Cokal D, Zimmerer V, Varley R, Watson S, Hinzen W. Comprehension of Embedded Clauses in Schizophrenia With and Without Formal Thought Disorder. The Journal of nervous and mental disease 2019, 207(5), 384-392.
  • Palmos AB, Watson S, Hughes T, Finkelmeyer A, McAllister-Williams RH, Ferrier N, Anderson IM, Nair R, Young AH, Strawbridge R, Cleare AJ, Chung R, Frissa S, Goodwin L, Hotopf M, Hatch SL, Wang H, Collier DA, Thuret S, Breen G, Powell TR. Associations between childhood maltreatment and inflammatory markers. BJ Psych Open 2019, 5(1), e3.
  • Clark JE, Watson S, Friston KJ. What is mood? A computational perspective. Psychological Medicine 2018, 48(14), 2277-2284.
  • Cokal D, Sevilla G, Jones WS, Zimmerer V, Deamer F, Douglas M, Spencer H, Turkington D, Ferrier N, Varley R, Watson S, Hinzen W. The language profile of formal thought disorder. npj Schizophrenia 2018, 4(1), 18.
  • Clark JE, Davidson SL, Maclachlan L, Newton JL, Watson S. Rethinking childhood adversity in chronic fatigue syndrome. Fatigue: Biomedicine, Health & Behavior 2018, 6(1), 20-29.
  • Lynn M, Maclachlan L, Finkelmeyer A, Clark J, Locke J, Todryk S, Ng W-F, Newton JL, Watson S. Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome. Mediators of Inflammation 2018, 2018, 3972104.
  • Douglas KM, Gallagher P, Robinson LJ, Carter JD, McIntosh VVW, Frampton CMA, Watson S, Young AH, Ferrier IN, Porter RJ. Prevalence of cognitive impairment in major depression and bipolar disorder. Bipolar Disorders 2018, 20(3), 260-274.
  • Finkelmeyer A, He J, Maclachlan L, Watson S, Gallagher P, Newton JL, Blamire AM. Grey and white matter differences in Chronic Fatigue Syndrome – A voxel-based morphometry study. NeuroImage: Clinical 2018, 17, 24-30.
  • Horne S, Hay K, Watson S, Anderson KN. An evaluation of sleep disturbance on in-patient psychiatric units in the UK. Psychiatrist 2018, 42(5), 193-197.
  • Zimmerer VC, Watson S, Turkington D, Ferrier IN, Hinzen W. Deictic and Propositional Meaning-New Perspectives on Language in schizophrenia. Frontiers in Psychiatry 2017, 8, 17.
  • Maclachlan L, Watson S, Gallagher P, Finkelmeyer A, Jason LA, Sunnquist M, Newton JL. Are current chronic fatigue syndrome criteria diagnosing different disease phenotypes?. PLoS ONE 2017, 12(10), e0186885.
  • Moss RA, Finkelmeyer A, Robinson LJ, Thompson JM, Watson S, Ferrier IN, Gallagher P. The impact of target frequency on intra-individual variability in euthymic bipolar disorder: A comparison of two sustained attention tasks. Frontiers in Psychiatry 2016, 7, 106.
  • Clark JE, Ng WF, Watson S, Newton JL. The aetiopathogenesis of fatigue: unpredictable, complex and persistent. British Medical Bulletin 2016, 117(1), 139-148.
  • McAllister-Williams RH, Anderson IM, Finkelmeyer A, Gallagher P, Grunze HCR, Haddad PM, Hughes T, Lloyd AJ, Mamasoula C, McColl E, Pearce S, Siddiqi N, Sinha BNP, Steen N, Wainwright J, Winter FH, Ferrier IN, Watson S, ADD Study Team. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. The Lancet Psychiatry 2016, 3(2), 117-127.
  • Clark JE, Osborne JW, Gallagher P, Watson S. A simple method for optimising transformation of non-parametric data: an illustration by reference to cortisol assays. Human Psychopharmacology: Clinical and Experimental 2016, 31(4), 259-267.
  • Gallagher P, Nilsson J, Finkelmeyer AE, Goshawk M, Macritchie KA, Lloyd AJ, Thompson JM, Porter RJ, Young AH, Ferrier IN, McAllister-Williams RH, Watson S. Neurocognitive intra-individual variability in mood disorders: effects on attentional response time distributions. Psychological Medicine 2015, 45(14), 2985-2997.
  • Wooderson SC, Gallagher P, Watson S, Young AH. An exploration of testosterone levels in patients with bipolar disorder. British Journal of Psychiatry Open 2015, 1(3), 136-138.
  • Gallagher P, Gray JM, Watson S, Young AH, Ferrier IN. Neurocognitive functioning in bipolar depression: a component structure analysis. Psychological Medicine 2014, 44(5), 961-974.
  • Moriarty AS, Bradley AJ, Anderson KN, Watson S, Gallagher P, McAllister-Williams RH. Cortisol awakening response and spatial working memory in man: a U-shaped relationship. Human Psychopharmacology: Clinical & Experimental 2014, 29(3), 295-298.
  • Watson S, Gallagher P, Dougall D, Porter R, Moncrieff J, Ferrier IN, Young AH. Childhood trauma in bipolar disorder. Australian & New Zealand Journal of Psychiatry 2014, 48(6), 564-570.
  • McAllister-Williams RH, Smith E, Anderson IM, Barnes J, Gallagher P, Grunze HCR, Haddad PM, House AO, Hughes T, Lloyd AJ, McColl EMM, Pearce SHS, Siddiqi N, Sinha B, Speed C, Steen IN, Wainwright J, Watson S, Winter FH, Ferrier IN. Study protocol for the randomised controlled trial: Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study). BMC Psychiatry 2013, 13, 205.
  • Coulthard K, Patel D, Brizzolara C, Morriss R, Watson S. A feasibility study of expert patient and community mental health team led bipolar psychoeducation groups: implementing an evidence based practice. BMC Psychiatry 2013, 13, 301.
  • Watson S, Gallagher P, Porter RJ, Smith MS, Herron LJ, Bulmer S, North-East Mood Disorders Clinical Research Group, Young AH, Ferrier IN. A Randomized Trial to Examine the Effect of Mifepristone on Neuropsychological Performance and Mood in Patients with Bipolar Depression. Biological Psychiatry 2012, 72(11), 943-949.
  • Watson S, Horton K, Bulmer S, Carlile J, Corcoran C, Gallagher P, Ferrier IN. Effect of aspirin on hypothalamic–pituitary–adrenal function and on neuropsychological performance in healthy adults: a pilot study. Psychopharmacology 2009, 205(1), 151-155.
  • Gallagher P, Watson S, Dye CE, Young A, Ferrier IN. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia. Journal of Psychiatric Research 2008, 42(12), 1037-1041.
  • Gallagher P, Watson S, Smith MS, Young AH, Ferrier IN. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophrenia Research 2007, 90(1-3), 258-265.
  • Watson S, Gallagher P, Smith MS, Young AH, Ferrier IN. Lithium, arginine vasopressin and the dex/CRH test in mood disordered patients. Psychoneuroendocrinology 2007, 32(5), 464-469.
  • Thompson JM, Gray JM, Hughes JH, Watson S, Young AH, Ferrier IN. Impaired working memory monitoring in euthymic bipolar patients. Bipolar Disorders 2007, 9(5), 478-489.
  • Watson S, Owen BM, Gallagher P, Hearn AJ, Young AH, Ferrier IN. Family history, early adversity and the hypothalamic-pituitary-adrenal (HPA) axis: Mediation of the vulnerability to mood disorders. Neuropsychiatric Disease and Treatment 2007, 3(5), 647-653.
  • Mackin P, Gallagher P, Watson S, Young A, Ferrier IN. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Australian and New Zealand Journal of Psychiatry 2007, 41(4), 321-326.
  • Watson S, Gallagher P, Smith MS, Ferrier IN, Young AH. The dex/CRH test-Is it better than the DST?. Psychoneuroendocrinology 2006, 31(7), 889-894.
  • Menon A, McAllister-Williams RH, Watson S. Quetiapine associated with increased libido. Journal of Psychopharmacology 2006, 20(1), 125-127.
  • Jenkins KS, Patel D, Jennings P, Scott M, Peacock S, Lawson VE, Wallace S, Ahuja N, Watson S. Pilot of a group psycho-education programme in bipolar disorder. Bipolar Disorders 2006, 8, 54-54.
  • Watson S, Thompson JM, Ritchie JC, Ferrier IN, Young AH. Neuropsychological impairment in bipolar disorder: The relationship with glucocorticoid receptor function. Bipolar Disorders 2006, 8(1), 85-90.
  • Vasudev A, Watson S, Lloyd AJ, Harrison CL, Young AH. Bipolar prescription patterns: a cohort follow-up analysis. Quarterly Journal of Mental Health 2006, 1(1).
  • Watson S, Chilton R, Fairchild H, Whewell P. Association between childhood trauma and dissociation among patients with borderline personality disorder. Australian and New Zealand Journal of Psychiatry 2006, 40(5), 478-481.
  • Watson S, Thompson JM, Malik N, Ferrier IN, Young AH. Temporal stability of the dex/CRH test in patients with rapid-cycling bipolar I disorder: A pilot study. Australian and New Zealand Journal of Psychiatry 2005, 39(4), 244-248.
  • Thompson JM, Gallagher P, Hughes JH, Watson S, Gray JM, Ferrier IN, Young AH. Neurocognitive impairment in euthymic patients with bipolar affective disorder. British Journal of Psychiatry 2005, 186, 32-40.
  • Mackin P, Watson S, Ferrier IN. Neurobiology of depression : focus on brain-derived neurotrophic factor, cortisol and their interactions. Depression: Mind & Body 2005, 2(1), 11-18.
  • Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biological Psychiatry 2005, 57(2), 155-161.
  • Ferrier IN, Chowdhury R, Thompson JM, Watson S, Young AH. Neurocognitive function in unaffected first-degree relatives of patients with bipolar disorder: A preliminary report. Bipolar Disorders 2004, 6(4), 319-322.
  • Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004, 29(8), 1538-1545.
  • Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. British Journal of Psychiatry 2004, 184, 496-502.
  • Hearn AJ, Gallagher P, Owen BM, Smith MS, Watson S, Young AH. Effect of sub-chronic hydrocortisone on responses to amphetamine in normal male volunteers. Psychopharmacology 2004, 171(4), 458-464.
  • Porter RJ, Gallagher P, Watson S, Smith MS, Young AH. Elevated prolactin responses to L-tryptophan infusion in medication-free depressed patients. Psychopharmacology 2003, 169(1), 77-83.
  • Young AH, Watson S, Gallagher P, Del-Estal D, Owen BM, Hearn AJ, Porter RJ. The effects of glucocorticoid antagonists in unipolar and bipolar disorders [abstract]. Biological Psychiatry 2002, 51(8 (s)), 83S abstract no. 244.
  • Watson S, Gallagher P, Del-Estal D, Hearn A, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with chronic depression. Psychological Medicine 2002, 32(6), 1021-1028.
  • Watson S, Porter RJ, Young AH. Effect of hydrocortisone on the pituitary response to growth hormone releasing hormone. Psychopharmacology 2000, 152(1), 40-46.
  • Watson S and Young A H. How and Why to change antidepressants. Update 1998, 56(9), 822-826.

• Conference Proceedings (inc. Abstracts)

  • Watson S. MR function in bipolar affective disorders. In: 17th Annual Conference of the International Society for Bipolar Disorders. 2015, Toronto, Canada: Wiley-Blackwell.
  • Anitema B, Hall S, Ahuja N, Preston S, Keown P, McKinnon I, Baker M, Hart Y, Cunningham M, Watson S. A pilot study of anti-NMDA receptor antibodies in psychosis. In: International Congress of the Royal College of Psychiatrists - Psychiatry: medicine and the future. 2012, Liverpool, UK: Royal College of Psychiatrists.
  • Gallagher P, Gray JM, Watson S, Young AH, Ferrier IN. Visuo-spatial memory in bipolar depression: Neuropsychological and HPA axis correlates. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2011, Harrogate: Sage Publications Ltd.
  • Watson S, Gallagher P, Herron LJ, Smith MS, Watkinson HMO, Harikumar TR, Carlile J, Young AH, Ferrier IN. The efficacy of mifepristone in bipolar depression - Effect on spatial working memory. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2011, Harrogate: Sage Publications Ltd.
  • Watson S, Bulmer S, Gallagher P, Svennson LJ, Smith MS, Watkinson HMO, Harikumar TR, Carlile J, Ferrier IN, Young AH. The efficacy of mifepristone in bipolar depression - Effect on mood symptoms. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2011, Harrogate: Sage Publications Ltd.
  • Watson S, Gallagher P, Porter RJ, Smith M, Elmslie JL, Ogilve A, Harikumar TR, Menon A, Carlile J, Makhoul S, Ferrier IN, Young AH. Efficacy of Mifepristone (RU-486) in the Treatment of Bipolar Depression. In: Biological Psychiatry: 64th Annual Convention of the Society of Biological Psychiatry. 2009, Vancouver, Canada: Elsevier Inc.
  • Watson S, Gallagher P, Horton K, Bulmer S, Corcoran C, Ferrier IN. Effect of Aspirin on Hypothalamic-Pituitary-Adrenal Function and on Neuropsychological Performance in Healthy Adults. In: Biological Psychiatry: 64th Annual Convention of the Society of Biological Psychiatry. 2009, Vancouver, Canada: Elsevier Inc.
  • Jenkins K, Patel D, Jennings P, Scott M, Peacock S, Ahuja N, Watson S. Pilot of a group psycho-education programme in bipolar disorder. In: General Adult Faculty meeting of the Royal College of Psychiatrists. 2005, Liverpool, UK.
  • Smith MS, Malik N, Gallagher P, Watson S, Mackin P, Ferrier IN, Young AH. Neurocognitive and neuroendocrine effects of mifepristone (RU-486) in schizophrenia. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2004, Harrogate, UK: Sage Publications Ltd.
  • Watson S, Malik N, Smith MS, Young AH, Ferrier IN. The cortisol response to the DEX/CRH test is stable over time in patients with rapid cycling bipolar disorder (RCBD). In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2003, Cambridge, UK: Sage Publications Ltd.
  • Young AH, Watson S, Gallagher P, Smith MS, Del-Estal D, Owen BM, Hearn A. Mifepristone (RU-486) in the treatment of bipolar disorder and schizophrenia. In: Biological Psychiatry: 58th Annual Convention and Scientific Program of the Society of Biological Psychiatry. 2003, San Francisco, California, USA: Elsevier Inc.
  • Watson S, Chilton R, Venn H, Cookson A, Whewell P. Early adverse life experiences in patients with borderline personality disorder. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2003, Cambridge, UK: Sage Publications Ltd.
  • Vasudev A, Watson S, Harrison CL, Lloyd A, Young AH. Bipolar prescription patterns. In: Journal of Psychopharmacology: Summer Meeting of the British Association for Psychopharmacology. 2003, Cambridge, UK: Sage Publications Ltd.
  • Collier A, Watson S, Morris M, Baylis PH, Ball S. Adipsic diabetes insipidus with aversion to drinking: diagnosis and combined pharmacological and psychological treatment. In: 18th Joint Meeting of the British Endocrine Societies. 1999, Bournemouth, UK.

• Editorial

  • Watson S, Porter RJ. Childhood adversity in bipolar disorder. Australian & New Zealand Journal of Psychiatry 2014, 48(11), 975-976.

• Letters

  • Costa T, Bagnall A, Murray S, Bailey K, MacGowan G, Ng W-F, McKinnon I, Watson S, McAllister-Williams RH. Role of autonomic dysregulation in quality of life and functional impairment in implantable cardioverter defibrillator patients. Journal of Psychosomatic Research 2023, 171, 111390.
  • Roberts G, Taylor J-P, O'Brien J, Thomas AJ. Authors' response. British Journal of Psychiatry 2021, 219(3), 523-524.
  • Sousa S, Robinson L, Franklin M, Watson S. Patient-reported and clinician-rated outcome measures: Complementary evidence from two different perspectives. Journal of Affective Disorders 2020, 276, 848-849.
  • Wahba M, Sousa S, Watson S, Strawbridge R, Young AH, Lingford-Hughes A. Authors' reply. British Journal of Psychiatry 2019, 215(3), 568-569.
  • Preston S, Watson S, Gallagher P. The role of mineralocorticoid receptor dysregulation in the neurocognitive impairment of patients recovered from depression: a commentary on "Associations between cognitive performance and cortisol reaction to the DEX/CRH test in patients recovered from depression". Psychoneuroendocrinology 2013, 38(3), 460-461.
  • Sigalas PD, Watson S. Early Adversity and Hypothalamus-Pituitary-Adrenal Axis Function: Cross-Diagnostic Common Findings in Different Studies. Biological Psychiatry 2011, 70(5), E29.
  • Watson S, Gallagher P, Smith MS, Ferrier IN, Young AH. The dex/CRH test and the DST in patients with bipolar disorder and major depressive disorder. Psychoneuroendocrinology 2007, 32(1), 92-94.
  • Watson S, Porter R. The role of hypothalamic-pituitary-adrenal axis dysfunction in the attenuated growth hormone response in adolescents with familial loading for affective disorder. Archives of General Psychiatry 2002, 59(2), 186-187.
  • Watson S, Young AM. The role of endogenous cortisol in neuroendocrine studies. Neuropsychopharmacology 2002, 26(3), 408.
  • Watson S, Young AH. Reduced dopaminergic activity in depressed suicides. Psychoneuroendocrinology 2001, 26(7), 757-757.
  • Watson S, Man MS. Serotonin, stress and corticoids. Journal of Psychopharmacology 2000, 14(4), 419-420.
  • Watson S, Young AH. Dopaminergic sensitivity and prediction of antidepressant response. Journal of Psychopharmacology 2000, 14(4), 419-419.

• Note

  • Watson S, Dodd A. Structured group psychoeducation in patients with bipolar disorder delays time to mania and time to any episode compared with a peer support group. Evidence-Based Mental Health 2017, 20(3), e15.

• Reviews

  • Comsa M, Anderson KN, Sharma A, Yadav VC, Watson S. The relationship between sleep and depression and bipolar disorder in children and young people. BJPsych Open 2022, 8(1), e27.
  • Kovacs TZ, Hill RW, Watson S, Turkington D. Clusters, lines and webs—so does my patient have psychosis? reflections on the use of psychiatric conceptual frameworks from a clinical vantage point. Philosophy, Ethics, and Humanities in Medicine 2022, 17, 6.
  • Pigott K, Galizia I, Vasudev K, Watson S, Geddes J, Young AH. Topiramate for acute affective episodes in bipolar disorder in adults. Cochrane Database of Systematic Reviews 2016, (9), CD003384.
  • Smart C, Strathdee G, Watson S, Murgatroyd C, McAllister-Williams RH. Early life trauma, depression and the glucocorticoid receptor gene - an epigenetic perspective. Psychological Medicine 2015, 45(16), 3393-3410.
  • Tomas C, Newton J, Watson S. Hypothalamic-pituitary-adrenal function in patients with chronic fatigue syndrome. ISRN Neuroscience 2013. In Press.
  • Tomas C, Newton J, Watson S. A review of hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. ISRN Neuroscience 2013, 2013, 784520.
  • Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH. Oxcarbazepine for acute affective episodes in bipolar disorder. COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2011, (12).
  • Venn HR, Watson S, Gallagher P, Young AH. Facial expression perception: An objective outcome measure for treatment studies in mood disorders?. International Journal of Neuropsychopharmacology 2006, 9(2), 229-245.
  • Porter RJ, Gallagher P, Watson S, Young AH. Corticosteroid-serotonin interactions in depression: A review of the human evidence. Psychopharmacology 2004, 173(1), 1-17.
  • McAllister-Williams RH, Watson S. Bipolar disorder ignored by the Mental Health National Service Framework but not forgotten by the British Association for Psychopharmacology. Journal of Psychopharmacology 2003, 17(4), 7-10.